Primer: Sionna Therapeutics (SION US) - Aug 2026
Sionna Therapeutics is a clinical-stage biopharmaceutical company sharply focused on developing novel small-molecule therapies for cystic...
103 Views
Aardvark Therapeutics (AARD) Six Month Summary: A Cold Debut That Froze the Biotech Market
Aardvark's biotech IPO priced at low end, opened underwater, highlighting lack of sector interest and market freeze in 2025.
482 Views
Sionna Therapeutics (SION) Six Month Summary: Hot Start, Cold Reality, and a Strong Spring Rebound
Sionna Therapeutics' successful IPO sees strong market debut with 38.9% premium, fueled by positive Phase I data for Metsera.
425 Views
Metsera Inc (MTSR) Six Month Summary: The Bright Spot in a Quiet Biotech Year
Metsera's stock offering priced above range, shares rally to $47.40, trajectory hinges on upcoming clinical trial data for MET-233i.
391 Views
Sionna Therapeutics Inc. (SION): RA Capital Backed Biotech IPO Booms in Debut
Biopharmaceutical company with potential cystic fibrosis treatment opens IPO above issue, but may not see strong aftermarket performance due to...
544 Views